Hib vaccine

The Hib vaccine is a vaccine used to prevent infections caused by Haemophilus influenzae type b (Hib). H. influenzae type b is a bacterium responsible for severe pneumonia, meningitis, and other invasive diseases almost exclusively in children under five years old. The introduction of the Hib vaccine has significantly reduced the incidence of these diseases.

History

The Hib vaccine was first developed in the 1980s. The first Hib vaccines were polysaccharide vaccines, which were not very effective in children under 18 months of age. In 1987, the first conjugate Hib vaccine was introduced, which was effective in infants. This marked a significant advancement in the prevention of Hib-related diseases.

Mechanism of Action

The Hib vaccine is a conjugate vaccine, which means it is made by chemically linking the polysaccharide capsule of the bacterium to a protein carrier. This linkage enhances the immune response in young children, who do not respond well to polysaccharide antigens alone. The vaccine stimulates the immune system to produce antibodies against the Hib bacteria, providing immunity against future infections.

Administration

The Hib vaccine is administered via intramuscular injection. It is often given as part of a combination vaccine, such as the DTaP-IPV-Hib vaccine, which also protects against diphtheria, tetanus, pertussis, and polio. The primary series of the Hib vaccine is typically given at 2, 4, and 6 months of age, with a booster dose at 12 to 15 months.

Efficacy

The Hib vaccine is highly effective, with studies showing over 95% efficacy in preventing invasive Hib disease. Since the introduction of the vaccine, the incidence of Hib disease has decreased by over 99% in countries with high vaccination coverage.

Safety

The Hib vaccine is considered very safe. Common side effects are mild and may include redness, swelling, or pain at the injection site, and fever. Serious side effects are rare.

Global Impact

The introduction of the Hib vaccine has had a profound impact on public health worldwide. In countries with high vaccination coverage, the incidence of Hib disease has been virtually eliminated. The World Health Organization (WHO) recommends the inclusion of the Hib vaccine in all routine infant immunization programs.

Also see

• Vaccination
• Pneumococcal vaccine
• Meningococcal vaccine
• Childhood immunization schedule